|Day Low/High||55.59 / 57.11|
|52 Wk Low/High||24.75 / 79.90|
The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 739,137 share increase in total short interest for Radius Health Inc , to 7,245,291, an increase of 11.36% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Here's a technical look at how to trade five stocks within range of triggering big breakouts.
SABCS to include three abstracts from the development program for RAD1901 as a potential treatment of ER-positive advanced breast cancer
Results from Phase 3 ACTIVE trial show abaloparatide significantly reduced the incidence of new vertebral fractures and nonvertebral fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo
Board members who sit on four or more boards may find it impossible to manage their time when faced with an insurgent investor or merger situation -- or both.
The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.
ASBMR Meeting to include an oral late-breaking presentation of the results of the clinical development of an optimized abaloparatide transdermal patch
Cramer says don't buy Tesaro but do buy Cirrus Logic.
Cramer says discipline is needed to start trimming positions and taking profits.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -
Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.
When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says
Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.